Abbott Prism Hepatitis B, C And HTLV I/II Assays Gain FDA Panel Nod
This article was originally published in The Gray Sheet
Executive Summary
Use of Abbott Laboratories' Prism automated blood screener in conjunction with its hepatitis B surface antigen assay detected an additional 26.3 potentially infectious blood units annually, the company told FDA's Blood Products Advisory Committee Sept 17.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.